A Phase 3 Dose Response Study to Assess the Safety and Efficacy of Nabiximols Oromucosal Spray (Sativex) in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis.
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 22 Aug 2016
At a glance
- Drugs Nabiximols (Primary)
- Indications Multiple sclerosis; Muscle spasticity
- Focus Therapeutic Use
- Sponsors GW Pharmaceuticals
- 22 Aug 2016 New trial record
- 10 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.